GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NRx Pharmaceuticals
NRx Pharmaceuticals is a biotech company focused on central nervous system drugs. Its stock price is highly volatile, reflecting its complex history of clinical trials and regulatory decisions.
Share prices of companies in the market segment - Pharma psycho
NRx Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, particularly suicidal depression and chronic pain. We've classified it in the "Pharma Psychology" segment. The chart below shows the overall dynamics in this complex yet socially important sector, where new approaches to treating mental disorders are being sought.
Broad Market Index - GURU.Markets
NRx Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly suicidal depression. Its focus on this issue makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how NRx compares to it.
Change in the price of a company, segment, and market as a whole per day
NRXP - Daily change in the company's share price NRx Pharmaceuticals
For NRx Pharmaceuticals, which treats suicidal depression, daily price change is a measure of extreme volatility. It reflects the market's reaction to research data and regulatory decisions, and is a critical parameter for risk assessment.
Daily change in the price of a set of shares in a market segment - Pharma psycho
For NRx Pharmaceuticals, which treats suicidal depression, daily price change is a measure of extreme volatility. It reflects the market's reaction to research data and regulatory decisions, and is a critical parameter for assessing risk.
Daily change in the price of a broad market stock, index - GURU.Markets
NRx Pharmaceuticals develops drugs to treat central nervous system disorders, including depression and suicidal tendencies. This is an extremely complex and socially important area of medicine. The company's stock price fluctuations reflect progress in this fight, and this pulse of hope contributes to the overall market dynamics on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NRx Pharmaceuticals
For NRx Pharmaceuticals, year-over-year performance is a story about its high-risk pipeline. Its 12-month market cap is highly volatile and dependent on news about its drugs for suicidal depression and COVID-19. Its valuation is a bet that at least one of these risky projects will reach the finish line.
Annual dynamics of market capitalization of the market segment - Pharma psycho
NRx Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing drugs for the treatment of central nervous system disorders. Its stock price is highly volatile and dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NRx, a biotech company researching CNS drugs, is one of the most speculative stories on the market. Its stock price is completely unrelated to the economy. Its chart reflects hopes, risks, and shifts in investor sentiment regarding its developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NRx Pharmaceuticals
NRx Pharmaceuticals is a biotech company focused on mental health treatments. Its monthly performance is highly volatile and dependent entirely on news. Clinical trial results and FDA decisions on its drugs are binary events that can cause sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
NRx Pharmaceuticals develops drugs for the treatment of suicidal depression and other central nervous system disorders. This is an area with a significant unmet need. The company's success depends on the results of clinical trials. The psychopharmaceutical sector's timeline reflects the high risks and social importance of the research conducted by companies like NRx.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
NRx Pharmaceuticals develops drugs for the treatment of central nervous system disorders, including suicidal depression. This is an area with a high unmet need. The company's shares are driven solely by news of clinical trials. Their performance is completely disconnected from the market and reflects hopes for a breakthrough in psychiatry.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NRx Pharmaceuticals
NRx Pharmaceuticals, a clinical-stage company developing drugs for the treatment of central nervous system disorders, including suicidal depression, is experiencing extreme volatility. Weekly stock performance hinges on news about clinical trials and FDA decisions, where the stakes are high.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
NRx Pharmaceuticals develops drugs for the treatment of central nervous system disorders, including suicidal depression. This is an area with a significant unmet need. The chart shows how the market is reacting to the company's news compared to overall trends in the psychopharmacology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NRx Pharmaceuticals is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that NRXP's performance is largely uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
NRXP - Market capitalization of the company NRx Pharmaceuticals
The NRx Pharmaceuticals chart is a financial map of drug discovery for the central nervous system. The company's market cap reflects the hopes for its drugs to treat suicidal depression and other mental disorders. Its volatility reflects the complex clinical trials and the enormous need for new treatments.
NRXP - Share of the company's market capitalization NRx Pharmaceuticals within the market segment - Pharma psycho
NRx Pharmaceuticals's stake in the psychopharmacology sector is focused on developing drugs for the treatment of suicidal depression and other mental disorders. Its market share is highly volatile and depends on the results of clinical trials of its innovative, but risky, drugs.
Market capitalization of the market segment - Pharma psycho
NRx Pharmaceuticals is a biotech company focused on drugs for the treatment of depression and suicidal ideation. The chart below shows the overall market capitalization of this complex sector. Its dynamics reflect the urgent need for new, fast-acting antidepressants.
Market capitalization of all companies included in a broad market index - GURU.Markets
NRx Pharmaceuticals develops drugs to treat suicidal depression and other central nervous system disorders. Its market capitalization reflects the complexity and importance of this field. The chart below shows the economic weight of companies working in the mental health field.
Book value capitalization of the company, segment and market as a whole
NRXP - Book value capitalization of the company NRx Pharmaceuticals
For NRx Pharmaceuticals, book value is its R&D capital. The chart below shows its financial resources for developing drugs for the central nervous system and other areas. Its dynamics reflect the company's complex journey through clinical trials and partner searches.
NRXP - Share of the company's book capitalization NRx Pharmaceuticals within the market segment - Pharma psycho
NRx Pharmaceuticals is a clinical-stage biotech company developing drugs for the treatment of mental disorders. Its value lies in its scientific platform. Its tangible asset share schedule will be minimal, as is typical for R&D companies.
Market segment balance sheet capitalization - Pharma psycho
NRx Pharmaceuticals is a clinical-stage biotech company. Its value is created in labs, not factories. This is a "lightweight" model. The chart below illustrates how much the biopharmaceutical industry as a whole relies on physical assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
NRx Pharmaceuticals' balance sheet represents capital focused on developing drugs for the treatment of suicidal depression and other central nervous system disorders. The book value chart shows the resources devoted to addressing some of the most complex and pressing issues in mental health.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NRx Pharmaceuticals
NRx Pharmaceuticals develops drugs to treat central nervous system disorders, such as suicidal depression. Its market capitalization is highly volatile and reflects the history of its clinical programs. The chart shows how the market reacts to regulatory announcements and trial data in this complex therapeutic area.
Market to book capitalization ratio in a market segment - Pharma psycho
NRx Pharmaceuticals is a biopharmaceutical company focused on central nervous system drugs. Its history is full of ups and downs. The chart shows how the market views its current pipeline and chances of success after previous failures, making it highly volatile.
Market to book capitalization ratio for the market as a whole
NRx Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system and respiratory diseases. The chart shows how the market values a company with a risky development pipeline. Its market capitalization is highly volatile and depends on news about clinical trials and regulatory decisions.
Debts of the company, segment and market as a whole
NRXP - Company debts NRx Pharmaceuticals
NRx Pharmaceuticals develops drugs to treat central nervous system diseases and life-threatening conditions. For a biotech company in clinical development, debt is a way to finance risky but potentially breakthrough medical research.
Market segment debts - Pharma psycho
NRx Pharmaceuticals develops drugs to treat central nervous system and respiratory diseases. Development-stage biotech companies require a constant influx of capital. This chart, showing general standards for the pharmaceutical sector, provides context for assessing how NRx funds its clinical programs while awaiting results.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NRx Pharmaceuticals
NRx Pharmaceuticals develops drugs to treat central nervous system disorders, including suicidal depression. This is a complex and socially significant area. This chart shows the company's reliance on debt to fund its clinical trials, which is a direct indicator of its financial risk in the event of failure.
Market segment debt to market segment book capitalization - Pharma psycho
Developing drugs for central nervous system diseases, like NRx Pharmaceuticals, is an extremely complex field with a high failure rate. This chart shows how the biotech sector finances its riskiest projects. It helps us understand how NRx's financial model, which often deals with "last resort" drugs, differs from other pharmaceutical companies.
Debt to book value of all companies in the market
NRx Pharmaceuticals develops drugs to treat central nervous system and respiratory diseases. This is a high-risk field requiring significant investment. The chart shows how their debt burden, required for clinical trials, compares to the overall market.
P/E of the company, segment and market as a whole
P/E - NRx Pharmaceuticals
This chart shows the valuation of NRx Pharmaceuticals, a biopharmaceutical company focused on psychiatry and respiratory diseases. For a company with a volatile clinical trial history, this valuation reflects investors' speculative expectations regarding the potential success of its drugs.
P/E of the market segment - Pharma psycho
This indicator represents the average valuation for the biotech sector in which NRx Pharmaceuticals operates. It reflects the overall level of hope and risk in the field of mental health treatments. The chart serves as a barometer of investor sentiment for the entire development segment in this complex field.
P/E of the market as a whole
NRx Pharmaceuticals is a biotech company developing drugs to treat suicidal depression and other central nervous system disorders. This is a high-risk, but also hugely promising, area. This chart shows the market's risk appetite. It helps understand how investors assess NRx's chances of success in one of the most challenging areas of pharmaceuticals and how this compares to overall trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NRx Pharmaceuticals
NRx Pharmaceuticals is a biotech company specializing in drugs for the treatment of central nervous system disorders, particularly suicidal depression and bipolar disorder. The company's future depends on the success of its clinical programs. This chart reflects the highly volatile investor expectations regarding its developments in this complex and risky area.
%20P%2FE%20NRx%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NRx-Pharmaceuticals&v=1772667927163 "Chart of the company's future (projected) P/E NRx Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma psycho
NRx Pharmaceuticals is a biopharmaceutical company focused on drugs for the treatment of central nervous system disorders, particularly suicidal depression and bipolar disorder. This chart reflects expectations for the biotech sector, helping to assess the market's view on this complex and risky area of psychiatry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772667927180 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
NRx Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as suicidal depression and bipolar disorder. This chart of overall expectations reflects investor sentiment toward the biotech company. Market optimism facilitates funding for solving complex problems in mental health, where innovation is highly needed.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772667927186 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on drugs for the treatment of depression and suicidality. This chart shows the cost of developing drugs for the central nervous system. Future profits depend on the success of clinical trials and approval of its innovative approaches to treating mental disorders.
Profit of companies in the market segment - Pharma psycho
Sagtec Global Ltd likely provides software development or IT consulting services. Its profitability depends on the demand for IT services and the availability of qualified specialists. This chart reflects a stable but competitive market, where the need for digitalization supports demand, but price pressure and the competition for talent are ongoing challenges.
Overall market profit
NRx Pharmaceuticals develops drugs for the treatment of central nervous system disorders, particularly suicidal depression and bipolar disorder. The company is working in an area with a high unmet medical need. Its success depends entirely on the results of clinical trials of its innovative approaches.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NRx Pharmaceuticals
NRx Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders, including suicidal depression and bipolar disorder. Its profit forecast hinges on the success of clinical trials. This chart reflects analysts' speculative expectations for its developments in the complex field of psychiatry.
%20profit%20of%20the%20company%20NRx%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NRx-Pharmaceuticals&v=1772667927409 "Graph of future (projected) profit of the company NRx Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma psycho
NRx Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders, including suicidal depression and chronic pain. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the enormous need for new treatments for severe mental disorders and complex pain syndromes.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772667927449 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
NRx Pharmaceuticals develops drugs to treat central nervous system disorders, such as suicidal depression. Demand for such drugs is huge, but development is risky. This earnings forecast schedule impacts investor appetite for biotech companies, especially those operating in complex and capital-intensive fields.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772667927503 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on drugs for the treatment of central nervous system disorders, including suicidal depression, and respiratory diseases. The chart reflects a highly speculative assessment of its development pipeline in areas with high unmet medical needs.
P/S market segment - Pharma psycho
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders, including suicidal depression and chronic pain. This chart shows the average valuation for the sector, allowing one to assess the market's perception of NRx's revenue potential for development in the complex field of psychiatry.
P/S of the market as a whole
NRx Pharmaceuticals develops drugs to treat central nervous system disorders, including suicidal depression and chronic pain. The company operates in a complex and socially significant field. This chart, showing average valuations, clearly demonstrates the gap between the valuations of traditional businesses and biotech companies with breakthrough potential in psychiatry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NRx Pharmaceuticals
NRx Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly suicidal depression. This chart reflects investor confidence in the future success of its drugs. The valuation is based on the enormous potential revenue if the drugs are approved for this challenging patient population.
%20P%2FS%20NRx%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NRx-Pharmaceuticals&v=1772667927709 "The graph of the company's future (projected) P/S NRx Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma psycho
NRx Pharmaceuticals develops drugs to treat central nervous system disorders, particularly suicidal depression and bipolar disorder. The chart shows how investors estimate NRx's future sales, reflecting the huge unmet need for effective and fast-acting antidepressants.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772667927782 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
This chart reflects the hopes surrounding the treatment of severe mental disorders. NRx Pharmaceuticals is developing drugs for patients with suicidal depression. Work in this extremely complex and important area supports investors' belief that new, more effective treatments can be found for even the most severe conditions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772667927831 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders, such as suicidal depression. Currently, the company has no commercial sales revenue. Its financial chart reflects investments in clinical trials and research.
Sales of companies in the market segment - Pharma psycho
NRx Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, including suicidal depression and bipolar disorder. This chart shows total revenue in the psychopharmaceuticals business. It illustrates the urgent need for new treatments for mental disorders, particularly for patients in crisis.
Overall market sales
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly suicidal bipolar disorder and chronic pain. Its future depends on the success of clinical trials. This overall economic climate impacts the availability of capital for mental health research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NRx Pharmaceuticals
NRx Pharmaceuticals develops drugs to treat central nervous system disorders, particularly suicidal depression. The company's future depends on the success of clinical trials. The chart shows analysts' speculative revenue forecasts, which are betting on a breakthrough in the treatment of severe mental disorders.
%20sales%20of%20the%20company%20NRx%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NRx-Pharmaceuticals&v=1772667927999 "Schedule of future (projected) sales of the company NRx Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma psycho
NRx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, particularly suicidal depression and chronic pain. This chart displays projected sales for the entire psychopharmaceutical segment, highlighting overall growth expectations for the mental health market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772667928027 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
NRx Pharmaceuticals is a biopharmaceutical company focused on drugs for the treatment of central nervous system disorders, including suicidal depression. Success depends on the results of clinical trials. This general economic activity schedule impacts the overall health of the healthcare system and its ability to implement new treatments for mental disorders.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772667928050 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NRx Pharmaceuticals
NRx Pharmaceuticals is a biotech company focused on drugs for the treatment of central nervous system disorders. This metric is a financial reflection of its scientific activity. It demonstrates the amount of investment in clinical trials required to bring new treatments for depression and other disorders to market.
Market segment marginality - Pharma psycho
NRx Pharmaceuticals develops drugs for the treatment of central nervous system and respiratory diseases. Being in the clinical stage, its financial metrics reflect its investment in R&D. This chart provides an overview of the company's operating model and cost structure compared to other companies in the psychopharmacology field.
Market marginality as a whole
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on drugs for the treatment of central nervous system disorders, including suicidal depression and chronic pain. Their future depends on the success of clinical trials. This gross margin curve doesn't affect their scientific activities, but it is important for attracting investment.
Employees in the company, segment and market as a whole
Number of employees in the company NRx Pharmaceuticals
NRx Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders, including suicidal depression. This chart shows the progress of a small team at the clinical stage. Growth here reflects clinical trial activity and efforts to obtain regulatory approval.
Share of the company's employees NRx Pharmaceuticals within the market segment - Pharma psycho
NRx Pharmaceuticals develops drugs to treat central nervous system disorders, particularly suicidal depression. This chart shows the percentage of clinicians and neuroscientists the company attracts in this complex area of psychiatry. Its team is working on developing fast-acting antidepressants.
Number of employees in the market segment - Pharma psycho
NRx Pharmaceuticals, Inc. is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, particularly suicidal depression and chronic pain. This chart shows overall employment in the psychopharmacology sector, illustrating the high need for new treatments for severe mental health conditions.
Number of employees in the market as a whole
NRx Pharmaceuticals is a pharmaceutical company developing drugs to treat central nervous system disorders, including suicidal depression and bipolar disorder. This is a critically important area of medicine. This overall employment chart also reflects the growth of the mental health sector, where companies developing new treatments are attracting investment and leading talent.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NRx Pharmaceuticals (NRXP)
NRx Pharmaceuticals, Inc. is a biopharmaceutical company developing drugs for the treatment of central nervous system and respiratory diseases. This chart is a prime example of biotech. The very high market capitalization per employee suggests that the market is not evaluating current operations, but the potential for breakthrough drugs being developed by a small scientific team.
%20of%20the%20company%20NRx%20Pharmaceuticals%20(NRXP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NRx-Pharmaceuticals-NRXP&v=1772667928433 "Chart of market capitalization per employee (in thousands of dollars) of the company NRx Pharmaceuticals (NRXP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
NRx Pharmaceuticals develops drugs to treat central nervous system disorders, including suicidal depression. This is an area of high social importance. This metric reflects the enormous value the market places on their developments. A high metric reflects the hope that their drugs will save lives and receive regulatory approval.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772667928441 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
NRx Pharmaceuticals is a biopharmaceutical company focused on central nervous system (CNS) treatments, including those for suicidal depression. Its market value is highly volatile and depends on clinical trial results and regulatory decisions. This reflects the high risk and potential social impact of its developments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772667928452 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NRx Pharmaceuticals (NRXP)
NRx Pharmaceuticals (NRXP) is a clinical-stage biotech R&D company focused on drugs for the treatment of the central nervous system, particularly suicidal depression. This is pure science. This metric measures their capital burn rate—the net loss (R&D expenses) per employee.
%20Chart%20NRx%20Pharmaceuticals%20(NRXP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NRx-Pharmaceuticals-NRXP&v=1772667928507 "Company Profit Per Employee (in thousands of dollars) Chart NRx Pharmaceuticals (NRXP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
NRx Pharmaceuticals is a biotech company developing drugs for the treatment of central nervous system disorders and depression. This metric is irrelevant at the clinical stage. The graph shows the industry norm. If successful, their drugs could capture a huge market, generating profit per employee many times higher than the industry benchmark.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772667928536 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
NRx Pharmaceuticals (NRXP) is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders (depression, suicidality) and respiratory diseases. This is R&D. This graph shows the economics of their clinical trials. The profit per employee is negative, as the team of scientists is working on future products.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772667928556 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NRx Pharmaceuticals (NRXP)
This chart for NRx Pharmaceuticals, a company developing drugs for diseases of the central nervous system, reflects the complex clinical development pipeline. Future revenue growth per employee depends on the success of its candidates for the treatment of suicidal depression and other disorders.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NRx-Pharmaceuticals-NRXP&v=1772667928570 "Sales chart per company employee NRx Pharmaceuticals (NRXP)")
Sales per employee in the market segment - Pharma psycho
NRx Pharmaceuticals (NRXP) is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders (depression, suicidality). This is R&D. This metric reflects the average revenue per employee for the segment. It helps assess the productivity of their R&D team in this complex therapeutic area.
Sales per employee for the market as a whole
NRx Pharmaceuticals (NRXP) is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders (depression) and respiratory diseases. Currently, its staff consists primarily of scientists. This metric for NRXP is pending and will only increase if clinical trials are successful and approval is obtained.
Short shares by company, segment and market as a whole
Shares shorted by company NRx Pharmaceuticals (NRXP)
NRx Pharmaceuticals is a biotech company with a history of failures, including failed attempts to treat COVID-19 and suicidal depression. This chart demonstrates the extreme skepticism of investors, who are betting that the company has no viable assets and that its management will not succeed in any of its projects.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NRx-Pharmaceuticals-NRXP&v=1772667928668 "Short Shares Chart for the Company NRx Pharmaceuticals (NRXP)")
Shares shorted by market segment - Pharma psycho
NRx Pharmaceuticals (NRXP) is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders (such as suicidal depression). This chart shows a general short position in the psychiatric pharmacology sector. It reflects high skepticism regarding their clinical data and chances of approval in this complex area.
Shares shorted by the overall market
NRx Pharmaceuticals operates in a high-risk market—central nervous system (CNS) pharmaceuticals. This chart reflects the general pessimism that is detrimental to biotech. If a company is dependent on FDA approval or new funding, a wave of market fear could deprive it of resources long before its drugs prove effective.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NRx Pharmaceuticals (NRXP)
This chart shows the extreme volatility of NRx Pharmaceuticals. The company operates in the complex field of treating central nervous system disorders, including suicidal depression. This is a binary event zone. News of successful trial progress (especially for their ketamine-based drug) triggers explosive "overheating" (above 70). Regulatory delays or FDA rejections, on the other hand, lead to immediate seller capitulation (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NRx-Pharmaceuticals-NRXP&v=1772667928710 "RSI 14 indicator chart for the company's stock NRx Pharmaceuticals (NRXP)")
RSI 14 Market Segment - Pharma psycho
NRx Pharma (NRXP) is a "biotech" (with a controversial reputation), a "hunter" for *depression* and *suicidal* (ketamine, Cyclurad). The "Pharma psycho" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It's vital to understand: is NRXP's volatility due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
NRx Pharmaceuticals (NRXP) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NRXP (NRx Pharmaceuticals)
NRx Pharmaceuticals is a biotech company focused on CNS drugs, particularly those for suicidal depression and PTSD. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials and FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NRXP-NRx-Pharmaceuticals&v=1772667928808 "A chart showing analyst consensus forecasts for the expected stock price. NRXP (NRx Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price NRXP (NRx Pharmaceuticals)
NRx Pharmaceuticals (NRXP) is a biotech "lottery" developing drugs for complex CNS disorders (such as suicidal depression). This chart is a barometer of their R&D. It measures the huge gap between the speculative price and the consensus target, reflecting whether analysts believe they can turn around their troubled assets.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NRXP-NRx-Pharmaceuticals&v=1772667928854 "A chart showing the difference between the consensus forecast and the actual stock price. NRXP (NRx Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
NRx Pharmaceuticals (NRXP) is a biotech company focused on treating depression (suicidal ideation) and chronic pain. This chart shows analysts' overall expectations for the psychopharmacology sector. It reflects the confidence experts have in the company's R&D pipeline in this complex medical field.
Analysts' consensus forecast for the overall market share price
NRx Pharmaceuticals is a biotech company specializing in CNS drugs, specifically ketamine-based treatments for suicidal depression. This chart shows the overall risk appetite. For NRx, which operates in the complex field of psychiatry, overall market optimism is critical to attracting the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NRx Pharmaceuticals
NRx Pharmaceuticals (NRXP) is a biotech company focused on the treatment of severe, life-threatening CNS conditions, primarily suicidal depression and bipolar disorder. This chart summarizes their R&D progress. It reflects their highly volatile and complex clinical development journey and their dialogue with the FDA in this highly complex therapeutic area.
AKIMA Market Segment Index - Pharma psycho
NRx Pharmaceuticals (NRXP) is a clinical-stage biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, particularly suicidal depression and bipolar disorder. The chart shows the segment average, allowing investors to assess how NRXP's risk compares to the average in the complex psychopharmacology sector.
The AKIM Index for the overall market
NRx Pharmaceuticals is a biopharmaceutical company developing ketamine-based treatments for bipolar depression and suicidal tendencies. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative psychiatric story compares to overall economic trends.
